Trials / Recruiting
RecruitingNCT06254261
A Study of RAY1225 in Participants With Obesity
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1225 | Administered SC |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2024-02-21
- Primary completion
- 2025-12-20
- Completion
- 2025-12-20
- First posted
- 2024-02-12
- Last updated
- 2025-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06254261. Inclusion in this directory is not an endorsement.